Pluri Inc. Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Pluri Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2023-12-31 was $573.00K, a 37.24% decline year-over-year.
- Pluri Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2023-09-30 was $836.00K, a 15.04% decline year-over-year.
- Pluri Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2022-12-31 was $913.00K.
- Pluri Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2022-09-30 was $984.00K.
| Period end | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 3 month | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 12 month |
|---|---|---|
| 2023-12-31 | $573.00K 10-Q · filed 2024-02-12 | |
| 2023-09-30 | $836.00K 10-Q · filed 2023-11-13 | |
| 2022-12-31 | $913.00K 10-Q · filed 2024-02-12 | |
| 2022-09-30 | $984.00K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |